S5 Ep47: FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC
Oct 4, 2021
16:52
forum Ask episode
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
Dr. Patel discusses the role of biomarker testing in lung cancer, the FDA approvals of amivantamab and mobocertinib in EGFR exon 20 insertion–positive NSCLC, and future research directions in this subset of lung cancer.
OncLive® On Air